Optimized ventricular restraint therapy: adjustable restraint is superior to standard restraint in an ovine model of ischemic cardiomyopathy.
OBJECTIVE
The effects of ventricular restraint level on left ventricular reverse remodeling are not known. We hypothesized that restraint level affects the degree of reverse remodeling and that restraint applied in an adjustable manner is superior to standard, nonadjustable restraint.


METHODS
This study was performed in 2 parts using a model of chronic heart failure in the sheep. In part I, restraint was applied at control (0 mm Hg, n = 3), low (1.5 mm Hg, n = 3), and high (3.0 mm Hg, n = 3) levels with an adjustable and measurable ventricular restraint (AMVR) device. Restraint level was not altered throughout the 2-month treatment period. Serial restraint level measurements and transthoracic echocardiography were performed. In part II, restraint was applied with the AMVR device set at 3.0 mm Hg (n = 6) and adjusted periodically to maintain that level. This was compared with restraint applied in a standard, nonadjustable manner using a mesh wrap (n = 6). All subjects were followed up for 2 months with serial magnetic resonance imaging.


RESULTS
In part I, there was greater and earlier reverse remodeling in the high restraint group. In both groups, the rate of reverse remodeling peaked and then declined as the measured restraint level decreased with progression of reverse remodeling. In part II, adjustable restraint resulted in greater reverse remodeling than standard restraint. Left ventricular end diastolic volume decreased by 12.7% (P = .005) with adjustable restraint and by 5.7% (P = .032) with standard restraint. Left ventricular ejection fraction increased by 18.9% (P = .014) and 14.4% (P < .001) with adjustable and standard restraint, respectively.


CONCLUSIONS
Restraint level affects the rate and degree of reverse remodeling and is an important determinant of therapy efficacy. Adjustable restraint is more effective than nonadjustable restraint in promoting reverse remodeling.
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Lawrence S
LS
Lee
Ravi K
RK
Ghanta
Suyog A
SA
Mokashi
Otavio
O
Coelho-Filho
Raymond Y
RY
Kwong
Michael
M
Kwon
Jian
J
Guan
Ronglih
R
Liao
Frederick Y
FY
Chen
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D004195:Disease Models, Animal; D004452:Echocardiography; D006333:Heart Failure / Q000503:physiopathology / Q000601:surgery*; D006334:Heart Function Tests; D006352:Heart Ventricles / Q000503:physiopathology / Q000601:surgery*; D008026:Ligation; D008279:Magnetic Resonance Imaging; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000097:blood; D034561:Sheep, Domestic; D020257:Ventricular Remodeling
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain; D020778:Matrix Metalloproteinase 2